ALK L1196M Gatekeeper Resistenzmutation
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BIO-ALK-L1196M |
|---|---|
| Art | Biomarker |
| Aliase | ALK L1196M Gatekeeper-MutationALK L1196M — мутація резистентності (gatekeeper)ALK TorwartALK p.L1196M |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Erkrankungen | DIS-IMT |
| Quellen | SRC-ALEX-PETERS-2017 SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Biomarker-Fakten
| Biomarker-Typ | gene_mutation |
|---|---|
| Angaben zur Mutation | {"exon": "23", "functional_impact": "gatekeeper resistance to crizotinib (1st-gen) and partial resistance to alectinib; sensitive to brigatinib, ceritinib, lorlatinib", "gene": "ALK", "hgvs_protein": "p.L1196M", "variant_type": "missense"} |
| Messung | VerfahrenctDNA NGS bei Progression; Tumorrebiopsie NGS Einheitencategorical (positive | negative); VAF % when reported |
| Nachschlagewerk für die Aktionsfähigkeit | ‚Gen‘: ‚ALK‘, ‚Variante‘:‚L1196M‘} |
| Verwandte Biomarker | BIO-ALK-FUSION BIO-ALK-REARRANGEMENT BIO-ALK-G1202R |
Anmerkungen
Classical ALK gatekeeper mutation (analogous to EGFR T790M, BCR::ABL1 T315I). Most frequently seen as acquired resistance after crizotinib (1st-gen). 2nd-generation TKIs (alectinib, brigatinib, ceritinib) retain activity — alectinib superiority over crizotinib in 1L (ALEX, Peters 2017) is partly explained by avoidance of L1196M-mediated resistance. Lorlatinib also active. Compound mutations involving L1196M (e.g., L1196M + G1202R) emerge under sequential TKI pressure and require trial-based strategies.
Verwendet von
Biomarker
BIO-ALK-G1202R- ALK G1202R Resistenzmutation
Warnhinweis
RF-IMT-TRANSFORMATION-PROGRESSION- IMT-Progression bei First-line Crizotinib (erworbene ALK Kinase-Domain-Resistenzmutation...